Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 11/20 | 0.46 |
| ▸ | HTR2C | P28335 | 3/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.43 |
| ▸ | HTR1D | P28221 | 2/20 | 0.43 |
| ▸ | HTR2B | P41595 | 2/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.43 |
| ▸ | HTR3A | P46098 | 2/20 | 0.42 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.42 |
| ▸ | HTR3B | O95264 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.42 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.42 |
| ▸ | HRH1 | P35367 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7401627 | 0.85 | HTR4 (0.56) | HTR4HTR2CADRA1AADRA2CHTR1D | |
| SCHEMBL7391971 | 0.82 | HTR4 (0.45) | HTR4HTR2CADRA1AADRA2CHTR1D | |
| SCHEMBL6263176 | 0.81 | HTR4 (0.58) | HTR4HTR2CADRA1AADRA2CHTR1D | |
| SCHEMBL7404756 | 0.81 | HTR4 (0.58) | HTR4HTR2CADRA1AADRA2CHTR1D | |
| SCHEMBL7405651 | 0.80 | HTR4 (0.55) | HTR4ADRA1AADRA2BADRA1BADRA2A | |
| Hydrochloric Acid SCHEMBL7399150 | 0.80 | HTR2C (0.59) | HTR4HTR2CADRA1AADRA2CHTR1D | |
| SCHEMBL8317708 | 0.78 | HTR4 (0.44) | HTR4HTR2CADRA1AADRA2CHTR1D | |
| SCHEMBL7395285 | 0.77 | HTR4 (0.42) | HTR4HTR2CADRA1AADRA2CHTR1D | |
| SCHEMBL7400000 | 0.76 | HTR4 (0.58) | HTR4HTR2CADRA1AADRA2CHTR1D | |
| SCHEMBL7360909 | 0.74 | HTR4 (0.52) | HTR4HTR2CADRA1AADRA2CHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9168250-B2 | Pharmaceutical composition for treating and/or preventing a pathology associated with an obsessional behavior or with obesity | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS (FR) | 2015-10-27 | — | — | US | claimed |
| US-20130274293-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING A PATHOLOGY ASSOCIATED WITH AN OBSESSIONAL BEHAVIOR OR WITH OBESITY | UNIVERSITÉ DE NÎMES (FR) | 2013-10-17 | — | — | US | claimed |
| US-9168250-B2 | Pharmaceutical composition for treating and/or preventing a pathology associated with an obsessional behavior or with obesity | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS (FR) | 2015-10-27 | — | — | US | disclosed |
| US-8859537-B2 | Pharmaceutical composition for treating and/or preventing a pathology associated with an obsessional behavior or with obesity | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS (FR) | 2014-10-14 | — | — | US | disclosed |
| US-20130274293-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING A PATHOLOGY ASSOCIATED WITH AN OBSESSIONAL BEHAVIOR OR WITH OBESITY | UNIVERSITÉ DE NÎMES (FR) | 2013-10-17 | — | — | US | disclosed |
| US-20090124592-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING A PATHOLOGY ASSOCIATED WITH AN OBSESSIONAL BEHAVIOR OR WITH OBESITY | CENTRE NAT DE LA RECHERCHE SCIENTIFIQUE (FR) | 2009-05-14 | — | — | US | disclosed |
| US-20060116341-A1 | Pharmaceutical composition for treating and/or preventing a pathology associated with an obsessional behavior or with obesity | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS, AN ORGANIZATION OF FRANCE (FR) | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274293-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING A PATHOLOGY ASSOCIATED WITH AN OBSESSIONAL BEHAVIOR OR WITH OBESITY | OPRL1, HTR4, OPRM1 | HTR4 2/4885HTR2C 19/4885ADRA1A 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.